Skip to main content
. 2013 May 3;27(7):841–847. doi: 10.1038/eye.2013.83

Table 1. Demographics and baseline characteristics.

Demographic/baseline characteristics Total population N=1328 BBFC N=427 Brinzolamide N=453 Brimonidine N=448
Age, years
 Mean±SD 64.7±10.5 64.8±10.8 64.6±10.2 64.6±10.6
 <65, n (%) 641 (48.3%) 202 (47.3%) 209 (46.1%) 230 (51.3%)
 ≥65, n (%) 687 (51.7%) 225 (52.7%) 224 (53.9%) 218 (48.7%)
 
Race, n (%)
 White 968 (72.9%) 317 (74.2%) 320 (70.6%) 331 (73.9%)
 Black 326 (24.5%) 98 (23.0%) 117 (25.8%) 111 (24.8%)
 Asian 17 (1.3%) 6 (1.4%) 10 (2.2%) 1 (0.2%)
 Multi-racial 3 (0.2%) 0 (0.0%) 1 (0.2%) 2 (0.4%)
 American Indian/Alaska Native 1 (0.1%) 1 (0.2%) 0 (0.0%) 0 (0.0%)
 Other 13 (1.0%) 5 (1.2%) 5 (1.1%) 3 (0.7%)
 
Sex, n (%)
 Male 552 (41.6%) 173 (40.5%) 194 (42.8%) 185 (41.3%)
 Female 776 (58.4%) 254 (59.5%) 259 (57.2%) 263 (58.7%)
 
Diagnosis, n (%)
 Ocular hypertension 385 (29.0%) 132 (30.9%) 130 (28.7%) 123 (27.5%)
 Open-angle glaucoma 943 (71.0%) 295 (69.1%) 323 (71.3%) 325 (72.5%)

Abbreviation: BBFC, brinzolamide 1%/brimonidine 0.2% fixed combination.

Demographics and baseline characteristics were presented from the intent-to-treat population.